Medical treatment of biliary tract cancer: from peri-operative to palliative care, what's on?

被引：0
|
作者：
Boucher, E. [1 ]
机构：
[1] Ctr Eugene Marquis, CS 44229, F-35042 Rennes, France
来源：
ONCOLOGIE | 2012年 / 14卷 / 03期
关键词：
Biliary tract cancer; Medical treatment; Perioperative treatment; Palliative therapy; Chemotherapy; Radiotherapy; PHASE-II TRIAL; UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA; QUALITY-OF-LIFE; GALLBLADDER CANCER; HILAR CHOLANGIOCARCINOMA; BILE-DUCT; LIVER-TRANSPLANTATION; NEOADJUVANT CHEMORADIATION; ADJUVANT CHEMOTHERAPY; PHOTODYNAMIC THERAPY;
D O I：
10.1007/s10269-012-2135-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Biliary tract cancers (BTCs) encompass different cancers: intrahepatic, Katskin tumor, gallbladder, and main bile duct cancer. Surgical management of these cancers is difficult and most patients with BTC are likely to present with an unresectable or metastatic disease. Although standard systemic chemotherapy approaches are emerging, the prognosis remains poor. Development of adaptive therapeutic strategies is ongoing, as a better knowledge about these tumors is emerging.
引用
收藏
页码：150 / 157
页数：8
相关论文
共 38 条
  • [11] A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer
    Mattiucci, Gian Carlo
    Autorino, Rosa
    Tringali, Andrea
    Perri, Vincenzo
    Balducci, Mario
    Deodato, Francesco
    Gambacorta, Maria Antonietta
    Mantini, Giovanna
    Tagliaferri, Luca
    Mutignani, Massimiliano
    Morganti, Alessio. Giuseppe
    BRACHYTHERAPY, 2015, 14 (03) : 401 - 404
  • [12] Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study
    Naminatsu Takahara
    Hiroyuki Isayama
    Yousuke Nakai
    Takashi Sasaki
    Kazunaga Ishigaki
    Kei Saito
    Dai Akiyama
    Rie Uchino
    Suguru Mizuno
    Hiroshi Yagioka
    Hirofumi Kogure
    Osamu Togawa
    Saburo Matsubara
    Yukiko Ito
    Nobuo Toda
    Minoru Tada
    Kazuhiko Koike
    Investigational New Drugs, 2017, 35 : 269 - 276
  • [13] Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study
    Takahara, Naminatsu
    Isayama, Hiroyuki
    Nakai, Yousuke
    Sasaki, Takashi
    Ishigaki, Kazunaga
    Saito, Kei
    Akiyama, Dai
    Uchino, Rie
    Mizuno, Suguru
    Yagioka, Hiroshi
    Kogure, Hirofumi
    Togawa, Osamu
    Matsubara, Saburo
    Ito, Yukiko
    Toda, Nobuo
    Tada, Minoru
    Koike, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (03) : 269 - 276
  • [14] What Happens Now? Psychosocial Care for Cancer Survivors After Medical Treatment Completion
    Stanton, Annette L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (11) : 1215 - 1220
  • [15] S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study
    Furuse, Junji
    Okusaka, Takuji
    Boku, Narikazu
    Ohkawa, Shinichi
    Sawaki, Akira
    Masumoto, Toshikazu
    Funakoshi, Akihiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 849 - 855
  • [16] S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study
    Junji Furuse
    Takuji Okusaka
    Narikazu Boku
    Shinichi Ohkawa
    Akira Sawaki
    Toshikazu Masumoto
    Akihiro Funakoshi
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 849 - 855
  • [17] A Retrospective Study of S-1 Monotherapy as Second-line Treatment for Patients with Advanced Biliary Tract Cancer
    Kobayashi, Satoshi
    Ueno, Makoto
    Ohkawa, Shinichi
    Andou, Tomoko
    Kameda, Ryo
    Yamamoto, Naoto
    Morinaga, Soichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (09) : 800 - 806
  • [18] Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives
    Shroff, Rachna T.
    Bachini, Melinda
    FUTURE ONCOLOGY, 2024, 20 (20) : 1435 - 1450
  • [19] Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer
    Kashiwa, Munenobu
    Maeda, Hiroyuki
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (04) : 1569 - 1580
  • [20] Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study
    Matsuyama, Ryusei
    Morioka, Daisuke
    Mori, Ryutaro
    Hiratani, Seigo
    Yabushita, Yasuhiro
    Ota, Yohei
    Kumamoto, Takafumi
    Taniguchi, Koichi
    Endo, Itaru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 949 - 955
1234